Matches in Wikidata for { <http://www.wikidata.org/entity/Q66346619> ?p ?o ?g. }
Showing items 1 to 55 of
55
with 100 items per page.
- Q66346619 description "clinical trial" @default.
- Q66346619 description "ensayu clínicu" @default.
- Q66346619 description "klinisch onderzoek" @default.
- Q66346619 description "клінічне випробування" @default.
- Q66346619 name "A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/" @default.
- Q66346619 name "A Combination Study of Kadcyla" @default.
- Q66346619 type Item @default.
- Q66346619 label "A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/" @default.
- Q66346619 label "A Combination Study of Kadcyla" @default.
- Q66346619 prefLabel "A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/" @default.
- Q66346619 prefLabel "A Combination Study of Kadcyla" @default.
- Q66346619 P1132 Q66346619-AF5A0933-C33A-44B4-8D14-1A72A9A13AF4 @default.
- Q66346619 P1476 Q66346619-B96B59C2-CAF3-4C52-BE2D-DE66AF1A8BE7 @default.
- Q66346619 P17 Q66346619-1DC06A4C-F234-4F1C-9617-D77EAF91F108 @default.
- Q66346619 P17 Q66346619-54C69FDD-CE29-4DCA-9938-E0FE0C05D5F7 @default.
- Q66346619 P17 Q66346619-5F2DB8E8-A2EB-4765-BAE5-D522AB5397B5 @default.
- Q66346619 P17 Q66346619-67A86703-22E1-4117-B69D-5AB8658DFFF9 @default.
- Q66346619 P17 Q66346619-69BC58B2-FD6D-41A8-AE43-3374491CED6C @default.
- Q66346619 P17 Q66346619-AE7D11DC-8D0D-401F-A90B-0EBA2C2FAC6A @default.
- Q66346619 P17 Q66346619-CFEB5258-14A4-4DBF-8976-2702547064E7 @default.
- Q66346619 P17 Q66346619-D124AED3-AECB-4E79-99F5-60457BC87340 @default.
- Q66346619 P17 Q66346619-EB47222F-2532-45D2-8EC9-EB4D5D599EC2 @default.
- Q66346619 P17 Q66346619-F4B43ADD-98B7-409D-B780-0ECA6B28A61B @default.
- Q66346619 P17 Q66346619-FCEFD181-908C-46E6-BF4F-E3764E933D32 @default.
- Q66346619 P1813 Q66346619-B78AD00F-AA8C-468E-A73C-8EF48EC80038 @default.
- Q66346619 P2899 Q66346619-93E11895-86F3-4C0A-A7A8-A76176C166B6 @default.
- Q66346619 P3098 Q66346619-6F56D6BE-D34C-41D3-BD0D-04B9BABC1B3C @default.
- Q66346619 P31 Q66346619-19B78839-DFA3-4058-80F4-6CC282867094 @default.
- Q66346619 P580 Q66346619-02FAA7B7-9CD3-4103-810C-E4E25CB004E8 @default.
- Q66346619 P582 Q66346619-1FEE58DA-1E67-49D9-9202-654365F19AA6 @default.
- Q66346619 P6099 Q66346619-46B88E11-5B08-4711-95D5-0947C3B8F7B7 @default.
- Q66346619 P8363 Q66346619-B4E4EA18-2F77-49F2-9F62-0843782CB962 @default.
- Q66346619 P859 Q66346619-06720C03-3F5C-4B4B-95C1-5D2888FCBFCE @default.
- Q66346619 P1132 "+182" @default.
- Q66346619 P1476 "Phase I Study of the Combination of Trastuzumab Emtansine (T-DM1) and Capecitabine in HER2-Positive Metastatic Breast Cancer and HER2-Positive Locally Advanced/Metastatic Gastric Cancer Patients, Followed by a Randomized, Open-Label Phase II Study of Trastuzumab Emtansine and Capecitabine Versus Trastuzumab Emtansine Alone in HER2-Positive Metastatic Breast Cancer" @default.
- Q66346619 P17 Q142 @default.
- Q66346619 P17 Q155 @default.
- Q66346619 P17 Q16 @default.
- Q66346619 P17 Q183 @default.
- Q66346619 P17 Q214 @default.
- Q66346619 P17 Q29 @default.
- Q66346619 P17 Q38 @default.
- Q66346619 P17 Q403 @default.
- Q66346619 P17 Q41 @default.
- Q66346619 P17 Q414 @default.
- Q66346619 P17 Q45 @default.
- Q66346619 P1813 "TRAXHER2" @default.
- Q66346619 P2899 "+18" @default.
- Q66346619 P3098 "NCT01702558" @default.
- Q66346619 P31 Q30612 @default.
- Q66346619 P580 "2012-12-03T00:00:00Z" @default.
- Q66346619 P582 "2017-05-31T00:00:00Z" @default.
- Q66346619 P6099 Q42824440 @default.
- Q66346619 P8363 Q78089383 @default.
- Q66346619 P859 Q212646 @default.